USPTO 2015–2025 USPTO PatentsView US Corporation

Depomed, Inc.

USPTO PatentsView assignee record - 14 granted patents across 4 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Depomed ranks #19,660 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 4 technology areas.

#19,660
of 49,997 US assignees by volume
21st percentile
by Innovation Score (26.6/100)
16.9
avg claims per patent
-100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19660 · US Corporation #19,660 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 14 grants
  • MID-PACK #19,660/49,997
  • PHOTO-FINISH Deals Realm
  • CPC-NARROW A61P · 4 areas
  • INNOV-THIN 26.6/100
  • CLAIMS-RICH 16.9 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Deals Realm LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Depomed’s 26.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Depomed

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Depomed's Innovation Score is 26.6/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Depomed?

Each dot is one of Depomed’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Depomed’s own 16.9 claims/patent is at or below the 17.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Depomed vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 13.913.91414.1 0102030 Granted patents (volume) Avg claims / patent DeWalch Technologies, Inc. - 14, 27.5DewalchDeals Realm LLC - 14, 1.93Deals RealmDelStar Technologies, Inc. - 14, 19.64DelstarDelta SubSea LLC - 14, 21.71Delta SubseaDexter Axle Company LLC - 14, 10.64Dexter AxleDigi-Star, LLC - 14, 17.93Digi-starDigital Innovations LLC - 14, 5.64Digital Innovatio…Directa Plus S.p.A. - 14, 18.29Directa Plus S p ADepomed, Inc. - 14, 16.93Depomed
Depomed vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Depomed's grants concentrate

Depomed, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (6 grants) versus a trough of 1 in 2016. By volume, Depomed sits between DeWalch Technologies, Inc. and Directa Plus S.p.A..

Who files at Depomed's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Depomed holds 14 patents at rank #19,674, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Depomed

By rank, the assignees closest to #19,674 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Depomed's primary technology class.

Depomed's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 21st percentile higher than 21% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 2015201620172018 2
USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Depomed, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 35.7%
2016 1 7.1%
2017 6 42.9%
2018 2 14.3%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Depomed, Inc.'s patent record in context - here's where to go next.

  • Depomed, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #19,660 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Depomed, Inc. against DeWalch Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 26.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.